Antiemetic Studies on the NK₁ Receptor Antagonist Aprepitant

By Stoutenburg John P.   Raftopoulos Harry  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 2, Iss. 5, 2004-09 ,pp. : 491-497

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

In vitro and in vivo pharmacology of S 16474, a novel dual tachykinin NK 1 and NK 2 receptor antagonist

By Robineau P.   Lonchampt M.   Kucharczyk N.   Krause J.E.   Regoli D.   Fauchere J.-L.   Prost J.-F.   Canet E.  

European Journal of Pharmacology, Vol. 294, Iss. 2, 1995-12 ,pp. : 677-684

Elsevier

Access to resources Recommend Favorite

The neurokinin₁ receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy

By Warr David  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 12, 2006-08 ,pp. : 1653-1658

Informa Healthcare

Access to resources Recommend Favorite

Effect of a novel NK 1 receptor selective antagonist (NKP608) on citric acid induced cough and airway obstruction

By El-Hashim A.Z.   Wyss D.   Lewis C.  

Pulmonary Pharmacology & Therapeutics, Vol. 17, Iss. 1, 2004-02 ,pp. : 11-18

Elsevier

Access to resources Recommend Favorite

The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines

By Muñoz Miguel  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 529-540

Springer Publishing Company

Access to resources Recommend Favorite